在全球指标性创新盛会——「2025日本东京天才发明展」上，生合生物（股票代码1295）再次以卓越研发实力和临床实证跃上国际舞台。旗下四大功能性益生菌——ABKefir^®、LDL557、FS4722、BY2齐获金牌荣耀，其中LDL557更因其创新性与应用潜力获得大会评审肯定，获颁大会特别奖，成为本届展会亮眼的焦点之一！

日本，在全球保健食品市场中占据着举足轻重的地位，其市场规模位居世界第二，仅次于美国。在全球保健食品市场上建立极为严格的标准体系，针对功能性食品更是设定高标准规格认证，此次金奖的殊荣，被视为获得亚洲高端市场的认可，符合日本市场对于功能性食品（FOSHU）设定的严苛标准。

ABKefir乳酸菌通过5+2共生发酵，可双向调节肠道、缓解乳糖不耐受、促进脂肪代谢，临床验证其安全有效；德氏乳杆菌乳亚种LDL557后生元，能抑制关节炎症、修复软骨组织；副干酪乳酪杆菌BY2，具有降胆固醇之中国发明专利，可降低血脂水平；植物乳植杆菌FS4722通过抑制尿酸生成、促进代谢，减少痛风风险并兼具抗炎作用^[1][2]。

生合生物持续聚焦益生菌／后生元精准营养应用，串联肠道健康、免疫调节、代谢支持与关节保健等多重健康议题，并透过多项试验与临床研究验证其效果，未来将推进更多创新解方，深化全球机能性食品与营养保健市场布局。

[1] 专利信息：
【植物乳植杆菌FS4722】获中国发明专利（ZL202210167880.6）；
【副干酪乳酪杆菌BY2】获中国发明专利（ZL202110911715.2）；
【德氏乳杆菌乳亚种LDL557】获中国台湾新型专利（I776433）；
【ABKEFIR®乳酸菌】获美国发明专利(US11839635B1)，中国台湾新型专利(M603759)，中国台湾发明专利（I854384）

[2] 参考文献

l  Lactiplantibacillus plantarum enables blood urate control in mice through degradation of nucleosides in gastrointestinal tract

l  Regulation of Hepatocellular Cholesterol Metabolism By Lactobacillus Paracasei BY2 and Its Embedding Delivery

l  Putative Probiotic Strains Isolated from Kefir Improve gastrointestinal health parameters in adults(a Randomized single-blind, placebo-controlled study)

l  Long-term probiotic intervention mitigates memory dysfunction through a novel H3K27me3-based mechanism in lead-exposed rats

l  AB-Kefir reduced body weight and ameliorated inflammation in adipose tissue of obese mice fed a high-fat diet, but not a high-sucrose diet

l  Interplay of yoga, physical activity, and probiotics in irritable bowel syndrome management A double-blind randomized study

l  AB-kefir modulates gut microbiota and ameliorates obesity, metabolic and vascular insulin resistance in high-fat diet-induced obese rats

l  Evaluate and compare the anti-obesity effects of two probiotic preparations in high-fat diet-induced obese mice

l  Lactobacillus and Bifidobacterium Improves Physiological Function and Cognitive Ability in Aged Mice by the Regulation of Gut Microbiota

l  Heat-Killed Lactobacillus delbrueckii subsp. lactis 557 Extracts Protect Chondrocytes from Osteoarthritis Damage by Reducing Inflammation An In Vitro Study

l  The Oral Administration of Lactobacillus delbrueckii subsp. lactis 557 (LDL557) Ameliorates the Progression of Monosod Iodoace

l  Oral administration of Lactobacillus delbrueckii subsp. lactis LDL557 attenuates airway inflammation and changes the gut microbiota in a Der p-sensitized mouse model of allergic asthma